Research Article
Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
Table 1
General data of the CRC patients in adjuvant/palliative chemotherapy (FOLFOX4) without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aStage of disease currently described by TNM, as published by the American Joint Committee on Cancer (AJCC) and American Cancer Society (ACS). |